NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 9 September 2011 The MHRA and CHM have published the September edition of Drug Safety Update This edition includes […]
Category Archives: Other therapeutics
NPC Archive Item: MHRA Drug Safety Update July 2011: paracetamol dosing in children and other drug safety issues
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 18 July 2011 The July 2011 edition of Drug Safety Update (DSU) highlights the changes to recommendations for paracetamol […]
NPC Archive Item: Risks of anticholinergic drugs on cognitive decline and mortality examined
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 14 July 2011 A large observational study found that medications with anticholinergic activity were associated with greater cognitive decline in some groups of patients and increased mortality, compared with […]
NPC Archive Item: ‘High risk’ prescribing in primary care – how prevalent is it?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 July 2011 A cross sectional analysis of 315 general practices in Scotland found that 14% of the patients defined as particularly vulnerable to adverse drug events because of […]
NPC Archive Item: MHRA Drug Safety Update gives updated safety advice for bisphosphonates and Yasmin
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 16 June 2011 The June 2011 edition of Drug Safety Update considers both the risk of femoral fractures with […]
NPC Archive Item: Eribulin▼ increases median overall survival by 2.5months in women with advanced breast cancer
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 14 June 2011 The EMBRACE study of women with heavily pre-treated metastatic or locally recurrent breast cancer (n=762) found that eribulin mesylate 1.4mg/m2 administered intravenously at days 1 and […]
NPC Archive Item: Observational studies find increased VTE with Yasmin
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 May 2011 Two observational studies (UK study and US study) have found that there is a two to three-fold increased relative risk of venous thromboembolism (VTE) associated with […]
NPC Archive Item: April Drug Safety Update from MHRA/CHM
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 13th April 2011 The MHRA and CHM have published the April edition of Drug Safety Update. This edition advises […]
NPC Archive Item: Olmesartan reduces disease oriented outcomes but may have potential cardiovascular safety concerns
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28th March 2011 The ROADMAP trial found olmesartan delayed the onset of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. While this disease-oriented outcome (DOO) suggested a potential benefit […]
NPC Archive Item: Antibiotics with hormonal contraception ─ key changes to advice
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 9th March 2011 New guidance was published in January 2011 by the Faculty of Sexual and Reproductive Healthcare on drug interactions with hormonal contraception. A key change is that […]